PHARMACYTE BIOTECH, INC. Current Federal Tax Expense (Benefit)
PHARMACYTE BIOTECH, INC. (PMCB) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-07-29
- PHARMACYTE BIOTECH, INC. current federal tax expense (benefit) for fiscal 2026 was $0.00.
- PHARMACYTE BIOTECH, INC. current federal tax expense (benefit) for fiscal 2025 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2026-04-30 | $0.00 10-K · filed 2026-07-29 |
| 2025-04-30 | $0.00 10-K · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |